{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:48:55Z","timestamp":1790196535521,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH141"],"award-info":[{"award-number":["ZR2024MH141"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31872754"],"award-info":[{"award-number":["31872754"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013317","name":"Shanxi Provincial Key Research and Development Project","doi-asserted-by":"publisher","award":["2019JZZY021014"],"award-info":[{"award-number":["2019JZZY021014"]}],"id":[{"id":"10.13039\/501100013317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jconrel.2025.113601","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:56:30Z","timestamp":1741143390000},"page":"113601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Multifunctional nanoparticle-mediated targeting of metabolic reprogramming and DNA damage response pathways to treat drug-resistant triple-negative breast cancer"],"prefix":"10.1016","volume":"381","author":[{"given":"Sifeng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2025.113601_bb0005","first-page":"121","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.jconrel.2025.113601_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202107690","article-title":"Dual-loaded liposomes tagged with hyaluronic acid have synergistic effects in triple-negative breast Cancer","volume":"18","author":"Dong","year":"2022","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113601_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113601_bb0020","first-page":"523","article-title":"PARPs pick-up","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113601_bb0025","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113601_bb0030","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cac2.12549","article-title":"The regulatory roles and clinical significance of glycolysis in tumor","volume":"44","author":"Qiao","year":"2024","journal-title":"Cancer Commun."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113601_bb0035","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113601_bb0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113601_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113601_bb0050","article-title":"Synthetic lethal strategies for the development of cancer therapeutics","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113601_bb0055","article-title":"Cancer cell metabolism and antitumour immunity","author":"De Martino","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113601_bb0060","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cmet.2022.12.003","article-title":"Immunoediting instructs tumor metabolic reprogramming to support immune evasion","volume":"35","author":"Tsai","year":"2023","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113601_bb0065","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","article-title":"Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-alpha","volume":"35","author":"Wu","year":"2023","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113601_bb0070","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cell.2023.11.022","article-title":"Metabolic regulation of homologous recombination repair by MRE11 lactylation","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"issue":"8021","key":"10.1016\/j.jconrel.2025.113601_bb0075","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.jconrel.2025.113601_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400297","article-title":"Mitochondria-targeted Nanoadjuvants induced multi-functional immune-microenvironment remodeling to sensitize tumor radio-immunotherapy","volume":"11","author":"Zhou","year":"2024","journal-title":"Adv. Sci."},{"issue":"42","key":"10.1016\/j.jconrel.2025.113601_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202104418","article-title":"Triple enzyme-regulated molecular hydrogels for carrier-free delivery of lonidamine","volume":"31","author":"Wu","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"16_suppl","key":"10.1016\/j.jconrel.2025.113601_bb0090","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1200\/JCO.2022.40.16_suppl.3102","article-title":"A study of senaparib in combination with temozolomide for the treatment of patients with advanced solid tumors and extensive-stage small cell lung cancer","volume":"40","author":"Gao","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113601_bb0095","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-024-03003-9","article-title":"Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial","volume":"30","author":"Wu","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113601_bb0100","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113601_bb0105","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.7150\/thno.23050","article-title":"Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer","volume":"8","author":"Dasa","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.113601_bb0110","article-title":"Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jconrel.2025.113601_bb0115","article-title":"Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor","volume":"26","author":"Zhu","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"51","key":"10.1016\/j.jconrel.2025.113601_bb0120","doi-asserted-by":"crossref","first-page":"14225","DOI":"10.1002\/anie.201408897","article-title":"Mitochondria-targeted Cancer therapy using a light-up probe with aggregation-induced-emission characteristics","volume":"53","author":"Hu","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2025.113601_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102368","article-title":"GSH-responsive prodrug-based nanodrugs for augmenting chemo-photodynamic synergistic therapy against tumors","volume":"57","author":"Shi","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.113601_bb0130","first-page":"414","article-title":"pH\/GSH dual responsive nanosystem for nitric oxide generation enhanced type I photodynamic therapy","volume":"34","author":"Zou","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2025.113601_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216820","article-title":"CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in triple negative breast cancer","volume":"589","author":"Orhan","year":"2024","journal-title":"Cancer Lett."},{"issue":"8014","key":"10.1016\/j.jconrel.2025.113601_bb0140","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","article-title":"The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer","volume":"629","author":"Abraham","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113601_bb0145","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.apsb.2022.10.002","article-title":"Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers","volume":"13","author":"Zhang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.113601_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122023","article-title":"Nanomedicines with high drug availability and drug sensitivity overcome hypoxia-associated drug resistance","volume":"294","author":"Liu","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113601_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2023.02.023","article-title":"Overcoming drug resistance with a docetaxel and disulfiram loaded pH-sensitive nanoparticle","volume":"356","author":"Swetha","year":"2023","journal-title":"J. Control. Release"},{"issue":"5930","key":"10.1016\/j.jconrel.2025.113601_bb0160","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113601_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113601_bb0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tibs.2018.10.011","article-title":"Lactate: a metabolic driver in the tumour landscape","volume":"44","author":"Ippolito","year":"2019","journal-title":"Trends Biochem.Sci."},{"key":"10.1016\/j.jconrel.2025.113601_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101059","article-title":"Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer","volume":"73","author":"Li","year":"2024","journal-title":"Drug Resist. Updat."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113601_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2024.07.011","article-title":"Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma","volume":"36","author":"Li","year":"2024","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113601_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202309094","article-title":"A PD-L1-targeting regulator for metabolic reprogramming to enhance glutamine inhibition-mediated synergistic antitumor metabolic and immune therapy","volume":"36","author":"Jin","year":"2024","journal-title":"Adv. Mater."},{"issue":"37","key":"10.1016\/j.jconrel.2025.113601_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202410241","article-title":"Nanoscale metal-organic layer reprograms cellular metabolism to enhance photodynamic therapy and antitumor immunity","volume":"63","author":"Lin","year":"2024","journal-title":"Angew. Chem.-Int. Edit."},{"key":"10.1016\/j.jconrel.2025.113601_bb0195","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jconrel.2022.05.010","article-title":"Biomimetic nanoparticles for effective mild temperature photothermal therapy and multimodal imaging","volume":"347","author":"Shu","year":"2022","journal-title":"J. Control. Release"},{"issue":"32","key":"10.1016\/j.jconrel.2025.113601_bb0200","doi-asserted-by":"crossref","first-page":"21156","DOI":"10.1021\/acsnano.4c04024","article-title":"Mitochondria-targeted multifunctional nanoprodrugs by inhibiting metabolic reprogramming for combating cisplatin-resistant lung cancer","volume":"18","author":"Lu","year":"2024","journal-title":"ACS Nano"},{"issue":"15","key":"10.1016\/j.jconrel.2025.113601_bb0205","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1021\/acs.chemrev.7b00042","article-title":"Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications","volume":"117","author":"Zielonka","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.113601_bb0210","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.mattod.2023.04.002","article-title":"Mitochondria-targeted metal\u2013organic frameworks for cancer treatment","volume":"66","author":"Tabish","year":"2023","journal-title":"Mater. Today"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113601_bb0215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-022-28440-3","article-title":"A non-catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis","volume":"13","author":"Blaha","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113601_bb0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"7381","key":"10.1016\/j.jconrel.2025.113601_bb0225","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113601_bb0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ctrv.2014.10.006","article-title":"Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51","volume":"41","author":"Ward","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113601_bb0235","first-page":"736","article-title":"USP14 is a deubiquitinase for Ku70 and critical determinant of non-homologous end joining repair in autophagy and PTEN-deficient cells","volume":"48","author":"Sharma","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2025.113601_bb0240","doi-asserted-by":"crossref","DOI":"10.1186\/1756-9966-31-99","article-title":"Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance","volume":"31","author":"Ma","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113601_bb0245","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592500210X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592500210X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:10:34Z","timestamp":1769220634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592500210X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"alternative-id":["S016836592500210X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113601","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multifunctional nanoparticle-mediated targeting of metabolic reprogramming and DNA damage response pathways to treat drug-resistant triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113601"}}